Zymeworks从皇家药店筹集了2.5亿美元,将Ziihera药物的未来使用费作为还款。 Zymeworks raised $250 million from Royalty Pharma, using future royalties from its drug Ziihera as repayment.

Zymeworks已经从皇家药厂获得了2.5亿美元的特许使用费支持资金,由其药物Ziiehera(zanidatamab-hrii)的30%的全球分层使用费支持。 Zymeworks has secured $250 million in royalty-backed funding from Royalty Pharma, backed by 30% of worldwide tiered royalties from its drug Ziihera (zanidatamab-hrii). 还款将来自这些版税，这些版税层级在个位数的低至中位数之间，Pharma将在2033年12月31日前获得票据金额的1.65倍，若延长则为1,925倍。 Repayment will come from these royalties, which tier in the low- to mid-single digits, with Royalty Pharma set to receive 1.65 times the note amount by December 31, 2033, or 1.925 times if extended. Zymeworks在还款期间保留70%的特许权使用费,并保留对监管和商业里程碑的所有权利,包括最多15亿美元的潜在付款。 Zymeworks retains 70% of the royalties during repayment and all rights to regulatory and commercial milestones, including up to $1.5 billion in potential payments.